Document is current
Any future updates will be listed below
-
Authors
Bay, Pierre https://orcid.org/0000-0002-6751-2110
Boizeau, Laure
Préau, Sébastien https://orcid.org/0000-0002-8638-7183
Favory, Raphaël
Guigon, Aurélie
Heming, Nicholas
Gault, Elyanne https://orcid.org/0000-0003-3855-9304
Pham, Tài https://orcid.org/0000-0002-4373-0711
Chaghouri, Amal
Turpin, Matthieu
Morand-Joubert, Laurence
Jochmans, Sébastien
Pitsch, Aurélia
Joseph, Adrien
Contou, Damien
Henry, Amandine https://orcid.org/0000-0002-8935-8185
Roux, Damien
Le Hingrat, Quentin https://orcid.org/0000-0001-9017-4941
Guillon, Antoine https://orcid.org/0000-0002-4884-8620
Handala, Lynda
Caruso, Stefano
Ader, Mohamed
Soulier, Alexandre
Pawlotsky, Jean-Michel https://orcid.org/0000-0003-0745-7559
Rodriguez, Christophe https://orcid.org/0000-0002-9817-5006
de Prost, Nicolas https://orcid.org/0000-0002-4833-4320
Fourati, Slim
- License Information
-
More Information
Article History
Received: 17 February 2025
Accepted: 16 February 2026
First Online: 9 March 2026
Competing interests
: Slim Fourati reports having served as a speaker for Sanofi, GlaxoSmithKline, AstraZeneca, MSD, Pfeizer, Cepheid and Moderna. Jean-Michel Pawlotsky reports having served as an advisor and/or speaker for Abbott, Abbvie, Diagnostics for the Real World, Gilead and GSK. Christophe Rodriguez reports having served as a speaker for Pfizer and Tecan. Nicolas de Prost reports having served as an advisor or speaker for Moderna and AstraZeneca. All other authors declare no competing interest.
: The study was approved by the Comité de Protection des Personnes Sud-Méditerranée I (N° EudraCT/ID-RCB: 2021-A02914-37). Informed consent was obtained from all patients or their relatives.
